Pia Alhopuro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pia Alhopuro has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Auli Karhu
Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland
1 shared publication - Kati Waltering
Institute of Medical Technology and Tampere University Hospital, University of Tampere, Tampere, Finland
1 shared publication - Lauri A. Aaltonen
Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland
1 shared publication - Robert Winqvist
Laboratory of Cancer Genetics and Tumor Biology, Translational Medicine Research Unit, Biocenter Oulu and Faculty of Medicine, Medical Research Center Oulu, University of Oulu, FI-90220 Oulu, Finland
1 shared publication - Tapio Visakorpi
Center for Cancer Eradication Research, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
1 shared publication
Latest Publications
- Open Access
- 17 September 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 263
Somatic mutation analysis of MYH11in breast and prostate cancer
Background: MYH11 (also known as SMMHC) encodes the smooth-muscle myosin heavy chain, which has a key role in smooth muscle contraction. Inversion at the MYH11 locus is one of the most frequent chromosomal aberrations found in acute myeloid leukemia. We have previously shown that MYH11 mutations occur in human colorectal cancer, and may also be associated with Peutz-Jeghers syndrome. The mutations found in human intestinal neoplasia result in unregulated proteins with constitutive motor activity, similar to the mutant myh11 underlying the zebrafish meltdown phenotype characterized by disrupted intestinal architecture. Recently, MYH1 and MYH9 have been identified as candidate breast cancer genes in a systematic analysis of the breast cancer genome. Methods: The aim of this study was to investigate the role of somatic MYH11 mutations in two common tumor types; breast and prostate cancers. A total of 155 breast cancer and 71 prostate cancer samples were analyzed for those regions in MYH11 (altogether 8 exons out of 42 coding exons) that harboured mutations in colorectal cancer in our previous study. Results: In breast cancer samples only germline alterations were observed. One prostate cancer sample harbored a frameshift mutation c.5798delC, which we have previously shown to result in a protein with unregulated motor activity. Conclusion: Little evidence for a role of somatic MYH11 mutations in the formation of breast or prostate cancers was obtained in this study.
- 17 September 2008
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 263
Open AccessSomatic mutation analysis of MYH11in breast and prostate cancer
Background: MYH11 (also known as SMMHC) encodes the smooth-muscle myosin heavy chain, which has a key role in smooth muscle contraction. Inversion at the MYH11 locus is one of the most frequent chromosomal aberrations found in acute myeloid leukemia. We have previously shown that MYH11 mutations occur in human colorectal cancer, and may also be associated with Peutz-Jeghers syndrome. The mutations found in human intestinal neoplasia result in unregulated proteins with constitutive motor activity, similar to the mutant myh11 underlying the zebrafish meltdown phenotype characterized by disrupted intestinal architecture. Recently, MYH1 and MYH9 have been identified as candidate breast cancer genes in a systematic analysis of the breast cancer genome. Methods: The aim of this study was to investigate the role of somatic MYH11 mutations in two common tumor types; breast and prostate cancers. A total of 155 breast cancer and 71 prostate cancer samples were analyzed for those regions in MYH11 (altogether 8 exons out of 42 coding exons) that harboured mutations in colorectal cancer in our previous study. Results: In breast cancer samples only germline alterations were observed. One prostate cancer sample harbored a frameshift mutation c.5798delC, which we have previously shown to result in a protein with unregulated motor activity. Conclusion: Little evidence for a role of somatic MYH11 mutations in the formation of breast or prostate cancers was obtained in this study.